Hormonal
Metformin treatment alters gut microbiota composition (increasing Escherichia coli, decreasing Intestinibacter bartlettii) to enhance the production of short-chain fatty acids (propionate and butyrate) and modulate bile acid pools, which mediates glucose-lowering effects.
If you take metformin, your gut bacteria are actively helping lower your blood sugar by producing beneficial fats (SCFAs) and signaling molecules. However, this same bacterial shift can cause stomach upset for about 30% of users. If you experience GI distress, it may be linked to this mechanism, and discussing management strategies with your provider is important.
Support for the causal effects of these GM differences in type 2 diabetes has been provided by randomized trials and studies in drug-naive individuals demonstrating that the GM compositional changes translate to enhanced production of propionate and butyrate (20,21) and modulation of bile acid pools (21), which may mediate some of the glucose-lowering effects of metformin (Fig. 3) (20–22,24).
Why this rating
Supported by randomized trials and studies in drug-naive individuals, though the paper notes the GM might also cause side effects.
Source
The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications—2023 <i>Diabetes</i>, <i>Diabetes Care</i>, and <i>Diabetologia</i> Expert Forum
Mariana X. Byndloss et al. · Diabetes Care · 2024
DOI 10.2337/dci24-0052
More from this paper
- Dietary fiber intake influences gut microbiota composition and short-chain fatty acid generation, which decreases inflammation and supports gut barrier maintenance, thereby potentially lowering type 2 diabetes risk.Good
- Genetic predisposition to higher gut microbial butyrate production potential is causally linked to improved insulin response during an oral glucose tolerance test, while higher fecal propionate levels are causally linked to an increased risk of type 2 diabetes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →